Annexon reported initial outcomes from 6 patients in the pivotal Phase 3 FORWARD study of tanruprubart for Guillain-Barré Syndrome. The data were presented at the World Muscle Society Meeting in Hiroshima.
published
Annexon reported initial outcomes from 6 patients in the pivotal Phase 3 FORWARD study of tanruprubart for Guillain-Barré Syndrome. The data were presented at the World Muscle Society Meeting in Hiroshima.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.